ReviewVaccines2026
Recombinant Antibody Vaccines for Targeted Antigen Delivery: Design Principles and Immunological Applications.
Review in Vaccines, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vaccines that elicit durable immune responses require efficient delivery of antigen to antigen-presenting cells (APCs), in combination with appropriate contextual signals that promote immunity. Recombinant antibody vaccines are a flexible platform for antigen delivery in which monoclonal antibodies (mAbs) or antibody-derived fragments carry antigenic cargo to chosen receptors on target cells. In this review, we examine the design principles, mechanisms, and applications of recombinant antibody vaccines, with a focus on strategies targeting dendritic cells (DCs). DCs can take up, process, and present antigen, leading to effective induction of adaptive immune responses. Targeting of DCs with recombinant antibody vaccines improves the efficiency of antigen delivery and allows finetuning of responses through choice of a targeting receptor, antigen, and adjuvant. Recombinant antibody vaccines have been evaluated across a variety of immunological settings, including for vaccination against viral, bacterial, and protozoan pathogens, therapeutic cancer vaccination, and inverse vaccination to promote antigen-specific tolerance in models of autoimmune disease. Collectively, these studies demonstrate the versatile applications of recombinant antibody vaccines, although continued work is needed to define the elements most likely to support translation to the clinic. Overall, recombinant antibody vaccines provide a modular platform for targeted antigen delivery and represent a promising strategy for design of next-generation vaccines.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.